CELU — Celularity Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1752828 ·
Last close
$0.90
Market Cap
$25.96M
52W High
$1.45
52W Low
$0.71
ADV30
150,902
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,104,000 | -3,270,000 | -22,058,000 | -24,362,000 | 107,329,000 | 6,175,000 | 145,391,000 |
| Sep 2025 | 5,284,000 | 1,380,000 | -12,900,000 | -23,076,000 | 114,239,000 | 120,000 | 134,333,000 |
| Jun 2025 | 5,736,000 | 494,000 | -15,864,000 | -24,524,000 | 120,283,000 | 863,000 | 145,780,000 |
| Mar 2025 | 11,426,000 | 7,872,000 | -10,486,000 | -19,754,000 | 128,876,000 | 293,000 | 134,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,257,000
Investing CF
$0
Financing CF
$18,649,000
CapEx
$-91,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-3.47
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-991,483,000
Inventory
$571,000
Receivables
$4,653,000
ST Investments
—
EBIT TTM
$-84,959,000
Pretax Income TTM
$-91,713,000
Interest Exp TTM
$6,754,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$26,550,000
EBITDA
$-54,013,000
Free Cash Flow
$-5,257,375
Enterprise Value
$94,023,880
Total Cash
$6,175,000
Total Debt
$74,713,000
Shares Out
28,945,961
Trailing EPS
$-3.47
Book Value
$-1.32
ROE
—
ROA
-30.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 26,550,000 | -61,308,000 | -91,716,000 | 107,329,000 | 145,391,000 | — | -13,254,000 |
| Dec 2024 | 54,220,000 | -38,551,000 | -57,892,000 | 132,682,000 | 123,845,000 | — | -6,401,000 |
| Dec 2023 | 22,771,000 | -76,479,000 | -196,295,000 | 143,889,000 | 102,929,000 | — | -38,685,000 |
| Dec 2022 | 17,975,000 | -148,267,000 | 14,192,000 | 401,066,000 | 202,165,000 | — | -137,876,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.57
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MDNAF | Medicenna Therapeutics Corp. | $26.14M | $0.31 | — |
| TPST | Tempest Therapeutics, Inc. | $26.21M | $1.77 | — |
| PTN | PALATIN TECHNOLOGIES INC | $25.70M | $14.44 | — |
| NXTC | NextCure, Inc. | $25.36M | $7.02 | — |
| OTLC | Oncotelic Therapeutics, Inc. | $26.67M | $0.06 | — |
News headlines (Yahoo Finance, 1h cache)
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
2026-05-06 13:00 · Yahoo
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
2026-05-01 20:30 · Yahoo
NEXGEL Appoints Ian Blackman as Chief Financial Officer
2026-04-27 13:00 · Yahoo
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
2026-04-21 13:00 · Yahoo
Celularity Announces Closing of Transaction with NexGel
2026-04-21 12:30 · Yahoo
NEXGEL, Inc. Q4 2025 Earnings Call Summary
2026-04-21 12:30 · Yahoo
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
2026-04-17 20:35 · Yahoo
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
2026-04-15 20:12 · Yahoo
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
2026-04-08 20:05 · Yahoo
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
2026-03-31 20:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.